##### Table of Contents



UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, DC 20549
 
 FORM 10-Q
 
  þ
    
    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
 For the quarterly period ended September 30, 2006
 OR
 o
    
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 For the transition period from to
 Commission File Number 0-6533
 BOSTON LIFE SCIENCES, INC.
 (Exact Name of Registrant as Specified in Its Charter)
 Delaware
    
    87-0277826(State or Other Jurisdiction of
    
    (IRS EmployerIncorporation or Organization)
    
    Identification No.)85 Main Street, Hopkinton, Massachusetts
    
    01748(Address of Principal Executive Offices)
    
    (Zip Code)
 (508) 497-2360
(Registrants Telephone Number, Including Area Code)
 Not Applicable
(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)
 
 þ o
  o o þ
 o þ




---



##### 



BOSTON LIFE SCIENCES, INC.
 INDEX TO FORM 10-Q
  
 PagePart I Financial InformationItem 1. Financial Statements (Unaudited)Condensed Consolidated Balance Sheets as of September 30, 2006 and December 31, 2005
    
    
    3Condensed Consolidated Statements of Operations for the three and nine months ended
September 30, 2006 and 2005, and for the period from inception (October 16, 1992) to
September 30, 2006
    
    
    4Condensed Consolidated Statements of Cash Flows for the three and nine months ended
September 30, 2006 and 2005, and for the period from inception (October 16, 1992) to
September 30, 2006
    
    
    5Notes to Condensed Consolidated Financial Statements
    
    
    6Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations
    
    
    15Item 3. Quantitative and Qualitative Disclosures About Market Risk
    
    
    24Item 4. Controls and Procedures
    
    
    24Part II Other InformationItem 1A. Risk Factors
    
    
    26Item 6. Exhibits
    
    
    44SIGNATURESEx-31.1 Section 302 Certification of CEOEx-31.2 Section 302 Certification of CFOEx-32.1 Section 906 Certification of CEOEx-32.2 Section 906 Certification of CFO
  ®
 2




---



##### Table of Contents



Part I  Financial Information
 
 Item 1  Financial Statements
 Boston Life Sciences, Inc.
 
 
 September 30,
    
    
    December 31,2006
    
    
    2005AssetsCurrent assets:Cash and cash equivalents
    
    $
    1,363,664
    
    
    $
    578,505Marketable securities
    
    
    
    
    
    
    8,750,832Other current assets
    
    
    475,022
    
    
    
    486,599Total current assets
    
    
    1,838,686
    
    
    
    9,815,936Fixed assets, net
    
    
    168,819
    
    
    
    275,802Other assets
    
    
    382,072
    
    
    
    423,750Total assets
    
    $
    2,389,577
    
    
    $
    10,515,488Liabilities and Stockholders (Deficit) EquityCurrent liabilities:Accounts payable and accrued expenses
    
    $
    2,513,422
    
    
    $
    2,288,890Note payable (Note 10)
    
    
    2,000,000
    
    
    
    Accrued lease (Note 5)
    
    
    30,024
    
    
    
    60,966Total current liabilities
    
    
    4,543,446
    
    
    
    2,349,856Accrued lease, excluding current portion (Note 5)
    
    
    245,764
    
    
    
    274,326Total liabilities
    
    
    4,789,210
    
    
    
    2,624,182Commitments and contingencies (Note 8)Stockholders (deficit) equity:Preferred stock, $.01 par value; 1,000,000 shares authorized; 25,000
shares designated Convertible Series A, 500,000 shares designated
Convertible Series D, and 800 shares designated Convertible Series
E; no shares issued and outstanding
    
    
    
    
    
    
    Common stock, $.01 par value; 80,000,000 shares authorized;
16,543,634 and 16,478,084 shares issued and outstanding at
September 30, 2006 and December 31, 2005,
respectively
    
    
    165,436
    
    
    
    164,781Additional paid-in capital
    
    
    126,484,843
    
    
    
    124,887,204Accumulated other comprehensive loss
    
    
    (20
    )
    
    
    (12,393
    )Deficit accumulated during development stage
    
    
    (129,049,892
    )
    
    
    (117,148,286
    )Total stockholders (deficit) equity
    
    
    (2,399,633
    )
    
    
    7,891,306Total liabilities and stockholders (deficit) equity
    
    $
    2,389,577
    
    
    $
    10,515,488
  3




---



##### Table of Contents



Boston Life Sciences, Inc.
 
 
 From Inception(October 16,Three months ended September 30,
    
    
    Nine months ended September 30,
    
    
    1992) to2006
    
    
    2005
    
    
    2006
    
    
    2005
    
    
    September 30, 2006Revenues
    
    $
    
    
    
    $
    
    
    
    $
    
    
    
    $
    
    
    
    $
    900,000Operating expenses:Research and development
    
    
    2,167,532
    
    
    
    1,678,783
    
    
    
    6,481,875
    
    
    
    4,411,531
    
    
    
    78,396,736General and administrative
    
    
    1,859,073
    
    
    
    1,897,892
    
    
    
    5,560,039
    
    
    
    3,898,556
    
    
    
    40,899,807Purchased in-process
research and development
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    12,146,544Total operating expenses
    
    
    4,026,605
    
    
    
    3,576,675
    
    
    
    12,041,914
    
    
    
    8,310,087
    
    
    
    131,443,087Loss from operations
    
    
    (4,026,605
    )
    
    
    (3,576,675
    )
    
    
    (12,041,914
    )
    
    
    (8,310,087
    )
    
    
    (130,543,087
    )Other expenses
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (2,232
    )
    
    
    (1,582,878
    )Interest expense
    
    
    (12,500
    )
    
    
    
    
    
    
    (12,500
    )
    
    
    (45,965
    )
    
    
    (4,314,917
    )Investment income
    
    
    26,623
    
    
    
    26,807
    
    
    
    152,808
    
    
    
    66,412
    
    
    
    7,390,990Net loss
    
    
    (4,012,482
    )
    
    
    (3,549,868
    )
    
    
    (11,901,606
    )
    
    
    (8,291,872
    )
    
    
    (129,049,892
    )Preferred stock
beneficial conversion
feature
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (8,062,712
    )Accrual of preferred
stock dividends and
modification of
warrants held by
preferred stockholders
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (715,515
    )
    
    
    (1,229,589
    )Net loss attributable
to common stockholders
    
    
    (4,012,482
    )
    
    
    (3,549,868
    )
    
    
    (11,901,606
    )
    
    
    (9,007,387
    )
    
    $
    (138,342,193
    )Basic and diluted net
loss attributable to
common stockholders per
share
    
    $
    (0.24
    )
    
    $
    (0.30
    )
    
    $
    (0.72
    )
    
    $
    (0.88
    )Weighted average common
shares outstanding
    
    
    16,522,554
    
    
    
    11,987,721
    
    
    
    16,510,738
    
    
    
    10,220,594
  4




---



##### Table of Contents



Boston Life Sciences, Inc.
 
 
 From Inception(October 16,Nine months ended
    
    
    1992) toSeptember 30,
    
    
    September 30,2006
    
    
    2005
    
    
    2006Cash flows from operating activities:Net loss
    
    $
    (11,901,606
    )
    
    $
    (8,291,872
    )
    
    $
    (129,049,892
    )Adjustments to reconcile net loss to net cash used for operating activities:Purchased in-process research and development
    
    
    
    
    
    
    
    
    
    
    12,146,544Write-off of acquired technology
    
    
    
    
    
    
    
    
    
    
    3,500,000Interest expense settled through issuance of notes payable
    
    
    
    
    
    
    
    
    
    
    350,500Non-cash interest expense
    
    
    
    
    
    
    43,900
    
    
    
    1,648,675Non-cash charges related to options, warrants and common stock
    
    
    1,593,389
    
    
    
    48,821
    
    
    
    5,873,965Amortization and depreciation
    
    
    144,164
    
    
    
    157,012
    
    
    
    2,545,613Changes in operating assets and liabilities:Decrease (increase) in other current assets
    
    
    11,577
    
    
    
    (291,485
    )
    
    
    383,941Increase in accounts payable and accrued expenses
    
    
    224,532
    
    
    
    439,914
    
    
    
    1,740,757(Decrease) increase in accrued lease
    
    
    (59,504
    )
    
    
    388,607
    
    
    
    275,788Net cash used for operating activities
    
    
    (9,987,448
    )
    
    
    (7,505,103
    )
    
    
    (100,584,109
    )Cash flows from investing activities:Cash acquired through Merger
    
    
    
    
    
    
    
    
    
    
    1,758,037Purchases of fixed assets
    
    
    (37,181
    )
    
    
    (88,315
    )
    
    
    (1,468,957
    )Decrease (increase) in other assets
    
    
    41,678
    
    
    
    (84,329
    )
    
    
    (735,707
    )Purchases of marketable securities
    
    
    (2,071,660
    )
    
    
    (14,154,003
    )
    
    
    (128,645,044
    )Sales and maturities of marketable securities
    
    
    10,834,865
    
    
    
    6,200,033
    
    
    
    128,645,024Net cash provided by (used for) investing activities
    
    
    8,767,702
    
    
    
    (8,126,614
    )
    
    
    (446,647
    )Cash flows from financing activities:Proceeds from issuance of common stock
    
    
    4,905
    
    
    
    18,830,243
    
    
    
    63,581,473Proceeds from issuance of preferred stock
    
    
    
    
    
    
    
    
    
    
    35,022,170Preferred stock conversion inducement
    
    
    
    
    
    
    
    
    
    
    (600,564
    )Proceeds from issuance of notes payable
    
    
    2,000,000
    
    
    
    
    
    
    
    8,585,000Proceeds from issuance of convertible debentures
    
    
    
    
    
    
    
    
    
    
    9,000,000Principal payments of notes payable
    
    
    
    
    
    
    
    
    
    
    (7,146,967
    )Dividend payments on Series E Cumulative Convertible Preferred Stock
    
    
    
    
    
    
    (314,987
    )
    
    
    (516,747
    )Payments of financing costs
    
    
    
    
    
    
    (65,421
    )
    
    
    (5,529,945
    )Net cash provided by financing activities
    
    
    2,004,905
    
    
    
    18,449,835
    
    
    
    102,394,420Net increase in cash and cash equivalents
    
    
    785,159
    
    
    
    2,818,118
    
    
    
    1,363,664Cash and cash equivalents, beginning of period
    
    
    578,505
    
    
    
    152,971
    
    
    
    Cash and cash equivalents, end of period
    
    $
    1,363,664
    
    
    $
    2,971,089
    
    
    $
    1,363,664Supplemental cash flow disclosures:Non-cash transactions (see Note 6)
  5




---



##### Table of Contents



Boston Life Sciences, Inc.
 
 
 1. Basis of Presentation
      2. Net Loss Per Share
  6




---



##### Table of Contents



3. Comprehensive Loss
  4. Accounting for Stock-Based Compensation
      Three months ended
    
    
    Nine months endedSeptember 30, 2006Research and development
    
    $
    168,843
    
    
    $
    514,103General and administrative
    
    
    315,690
    
    
    
    976,070$
    484,533
    
    
    $
    1,490,173Impact on basic and diluted net loss attributable to common stockholders per share
    
    $
    (0.03
    )
    
    $
    (0.09
    )
 7




---



##### Table of Contents



Three months ended
    
    
    Nine months endedSeptember 30, 2005Net loss, as reported
    
    $
    (3,549,868
    )
    
    $
    (8,291,872
    )Add: Stock-based employee compensation expense (benefit) recognized
    
    
    
    
    
    
    Deduct: Total stock-based employee compensation expense determined under
fair value based methods for all awards
    
    
    (389,636
    )
    
    
    (1,303,866
    )Pro forma net loss
    
    $
    (3,939,504
    )
    
    $
    (9,595,738
    )Accrual of preferred stock dividends and modification of warrants held by
preferred stockholders
    
    
    
    
    
    
    (715,515
    )Pro forma net loss attributable to common stockholders
    
    $
    (3,939,504
    )
    
    $
    (10,311,253
    )Basic and diluted loss attributable to common stockholders per common share:As reported
    
    $
    (0.30
    )
    
    $
    (0.88
    )Pro forma
    
    $
    (0.33
    )
    
    $
    (1.01
    )
  Three months ended September 30,
    
    Nine months ended September 30,2006
    
    2005
    
    2006
    
    2005Expected term
    
    6 years
    
    3 years
    
    6 years
    
    3 yearsRisk-free interest rate
    
    4.5% - 5.0%
    
    4.2% - 4.3%
    
    4.3% - 5.0%
    
    3.4% - 4.3%Stock volatility
    
    90%
    
    100%
    
    90%
    
    100%Dividend yield
    
    0%
    
    0%
    
    0%
    
    0%
       2006
    
    
    2005Weighted-
    
    
    
    
    
    
    Weighted-Average
    
    
    
    
    
    
    AverageShares
    
    
    Exercise Price
    
    
    Shares
    
    
    Exercise PriceOutstanding at beginning of year
    
    
    2,590,152
    
    
    $
    4.23
    
    
    
    1,484,521
    
    
    $
    5.89Granted
    
    
    1,062,000
    
    
    
    2.66
    
    
    
    1,673,494
    
    
    
    2.60Exercised
    
    
    (750
    )
    
    
    2.22
    
    
    
    
    
    
    
    Forfeited and expired
    
    
    (181,337
    )
    
    
    9.55
    
    
    
    (513,818
    )
    
    
    2.43Outstanding at end of period
    
    
    3,470,065
    
    
    $
    3.47
    
    
    
    2,644,197
    
    
    $
    4.43Options exercisable at end of period
    
    
    1,943,670
    
    
    $
    4.03
    
    
    
    1,364,743
    
    
    $
    5.96
 8




---



##### Table of Contents



Options Outstanding
    
    
    Options ExercisableWeighted-
    
    
    
    
    
    
    
    
    
    
    WeightedAverage
    
    
    Weighted-
    
    
    
    
    
    
    Average
    
    
    Weighted-Remaining
    
    
    Average
    
    
    
    
    
    
    Remaining
    
    
    AverageNumber
    
    
    Contractual
    
    
    Exercise
    
    
    Number
    
    
    Contractual
    
    
    ExerciseRange of Exercise Prices
    
    Outstanding
    
    
    Life
    
    
    Price
    
    
    Exercisable
    
    
    Life
    
    
    Price$  1.35  $  2.00
    
    
    100,500
    
    
    8.9 years
    
    $
    1.97
    
    
    
    38,972
    
    
    8.9 years
    
    $
    1.96$  2.01  $  3.00
    
    
    2,037,516
    
    
    8.2 years
    
    
    2.38
    
    
    
    1,023,226
    
    
    7.4 years
    
    
    2.35$  3.10  $  4.65
    
    
    1,013,363
    
    
    8.5 years
    
    
    3.63
    
    
    
    562,786
    
    
    8.3 years
    
    
    3.59$  4.99  $  6.96
    
    
    132,500
    
    
    2.9 years
    
    
    5.50
    
    
    
    132,500
    
    
    2.9 years
    
    
    5.50$  8.95  $13.06
    
    
    80,740
    
    
    2.0 years
    
    
    10.63
    
    
    
    80,740
    
    
    2.0 years
    
    
    10.63$15.62  $22.36
    
    
    105,446
    
    
    1.9 years
    
    
    16.44
    
    
    
    105,446
    
    
    1.9 years
    
    
    16.443,470,065
    
    
    7.8 years
    
    $
    3.47
    
    
    
    1,943,670
    
    
    6.9 years
    
    $
    4.03
  5. Relocation and Sublease
     9




---



##### Table of Contents



Cash Payments,Accrual at
    
    
    Net of Sublease
    
    
    Accrual atDecember 31, 2005
    
    
    Receipts 2006
    
    
    September 30, 2006Lease Amendment
    
    $
    335,292
    
    
    $
    59,504
    
    
    $
    275,788Short-term portion of lease accrual
    
    
    60,966
    
    
    
    
    
    
    
    30,024Long-term portion of lease accrual
    
    $
    274,326
    
    
    
    
    
    
    $
    245,764
  6. Stockholders Equity
 Reverse Stock Split
  Preferred Stock
  Warrant Exercises
  Private Placement
  10




---



##### Table of Contents



Cancellation and Regrant of Stock Options
  Rights Agreement
  7. Severance and Settlement Agreement and Release
  8. Commitments and Contingencies
  License Agreements
  11




---



##### Table of Contents



Contingencies
  Guarantor Arrangements
   9. FluoroPharma, Inc. Amendment
  10. Notes Payable to Significant Stockholders
  12




---



##### Table of Contents



11. Related Party Transactions
  12. New Accounting Pronouncement
 .
   13




---



##### Table of Contents



14




---



##### Table of Contents



Item 2  Managements Discussion and Analysis of Financial Condition and Results of Operations
  Overview
 Description of Company
     ®
  15




---



##### Table of Contents



Recent Developments
       Product Development
 Molecular Imaging Program
  16




---



##### Table of Contents



Axon Regeneration Program
  17




---



##### Table of Contents



Parkinsons Disease Therapeutic Program
  Ocular Therapeutic Program
  Nature Neuroscience
 Sales and Marketing and Government Regulation
  18




---



##### Table of Contents



Research and Development
  3rd QuarterProgram
    
    2006
    
    Year to Date
    
    CumulativeMolecular Imaging
    
    $
    913,000
    
    
    $
    2,898,000
    
    
    $
    22,157,000Axon Regeneration
    
    $
    273,000
    
    
    $
    770,000
    
    
    $
    10,009,000Parkinsons Disease Therapeutic
    
    $
    49,000
    
    
    $
    99,000
    
    
    $
    858,000Ocular Therapeutic
    
    $
    61,000
    
    
    $
    193,000
    
    
    $
    368,000
  Critical Accounting Policies and Estimates
  Marketable Securities
  19




---



##### Table of Contents



Research Contracts
  Fair Value and Classification of Equity Instruments
    Lease Accrual
  Stock-Based Compensation
  20




---



##### Table of Contents



Results of Operations
 Three months ended September 30, 2006 and 2005
    21




---



##### Table of Contents



Nine months ended September 30, 2006 and 2005
        22




---



##### Table of Contents



Liquidity and Capital Resources
    Date
    
    Net Proceeds Raised
    
    Securities IssuedAugust 2006
    
    $2.0 million
    
    Notes payableSeptember 2005
    
    $12.8 million
    
    Common stockMarch 2005
    
    $5.0 million
    
    Common stockDecember 2003
    
    $7.0 million
    
    Convertible preferred stock and
warrants
    Contractual Obligations and Commitments
  23




---



##### Table of Contents



New Accounting Pronouncement
 .
   
 Item 3  Quantitative and Qualitative Disclosures About Market Risk
  
 Item 4  Controls and Procedures
  24




---



##### Table of Contents



25




---



##### Table of Contents



Part II  Other Information
 
 Item 1A  Risk Factors
    Risks Related to our Financial Results and Need for Additional Financing
 WE ARE A DEVELOPMENT STAGE COMPANY. WE HAVE INCURRED LOSSES FROM OUR OPERATIONS SINCE INCEPTION AND
ANTICIPATE LOSSES FOR THE FORESEEABLE FUTURE. WE WILL NOT BE ABLE TO ACHIEVE PROFITABILITY UNLESS
WE OBTAIN REGULATORY APPROVAL AND MARKET ACCEPTANCE OF OUR PRODUCT CANDIDATES.
  26




---



##### Table of Contents



WE WILL NEED SUBSTANTIAL ADDITIONAL FUNDING IN ORDER TO CONTINUE OUR BUSINESS AND OPERATIONS. IF WE
ARE UNABLE TO SECURE SUCH FUNDING ON ACCEPTABLE TERMS, WE MAY NEED TO
CEASE OPERATIONS SIGNIFICANTLY REDUCE, DELAY
OR CEASE ONE OR MORE OF OUR RESEARCH OR DEVELOPMENT PROGRAMS, OR SURRENDER RIGHTS TO SOME OR ALL OF
OUR TECHNOLOGIES.
  
    
    The scope, rate of progress and cost of our clinical trials and other research and development activities;
    
    Future clinical trial results;
    
    The terms and timing of any collaborative, licensing and other arrangements that we may establish;
    
    The cost and timing of regulatory approvals and of establishing sales, marketing and distribution capabilities;
    
    The cost of establishing clinical and commercial supplies of our product candidates and any products that we may develop;
    
    The cost of obtaining and maintaining licenses to use patented technologies;
    
    The effect of competing technological and market developments; and
    
    The cost of filing, prosecuting, defending and enforcing any patent claims and other
intellectual property rights and other patent-related costs, including litigation costs and
the results of such litigation.
     27




---



##### Table of Contents



CHANGES IN ESTIMATES UNDER FINANCIAL ACCOUNTING STANDARDS RELATED TO SHARE-BASED PAYMENTS COULD
HAVE A MATERIAL ADVERSE IMPACT ON OUR REPORTED RESULTS OF OPERATIONS.
  OUR ESTIMATES OF OUR LIABILITY UNDER OUR BOSTON, MASSACHUSETTS LEASE MAY CHANGE.
  Risks Related to Commercialization
 OUR SUCCESS DEPENDS ON OUR ABILITY TO SUCCESSFULLY DEVELOP OUR PRODUCT CANDIDATES INTO COMMERCIAL
PRODUCTS.
  EVEN IF WE RECEIVE APPROVAL TO MARKET OUR DRUG CANDIDATES, THE MARKET MAY NOT BE RECEPTIVE TO OUR
DRUG CANDIDATES UPON THEIR COMMERCIAL INTRODUCTION, WHICH COULD PREVENT US FROM SUCCESSFULLY
COMMERCIALIZING OUR PRODUCTS AND FROM BEING PROFITABLE.
   
    
    The timing of our receipt of any marketing approvals, the terms of any approval and the
countries in which approvals are obtained;
 28




---



##### Table of Contents




    
    The safety, efficacy and ease of administration of our products;
    
    The competitive pricing of our products;
    
    The success of our education and marketing programs;
    
    The sales and marketing efforts of competitors; and
    
    The availability and amount of government and third-party payor reimbursement.
  ACQUISITIONS PRESENT MANY RISKS, AND WE MAY NOT REALIZE THE ANTICIPATED FINANCIAL AND STRATEGIC
GOALS FOR ANY SUCH TRANSACTIONS.
  
    
    We may find that the acquired company or assets do not further our business strategy, or
that we overpaid for the company or assets, or that economic conditions change, all of which
may generate a future impairment charge;
    
    We may have difficulty integrating the operations and personnel of the acquired business,
and may have difficulty retaining the key personnel of the acquired business;
    
    We may have difficulty incorporating the acquired technologies;
    
    We may encounter technical difficulties or failures with the performance of the acquired
technologies or drug products or may experience unfavorable results in the clinical studies
related to such technologies or products;
    
    We may face product liability risks associated with the sale of the acquired companys
products;
    
    Our ongoing business and managements attention may be disrupted or diverted by
transition or integration issues and the complexity of managing diverse locations;
    
    We may have difficulty maintaining uniform standards, internal controls, procedures and policies across locations;
    
    The acquisition may result in litigation from terminated employees or third-parties; and
    
    We may experience significant problems or liabilities associated with product quality, technology and legal contingencies.
   29




---



##### Table of Contents



Risks Related to Regulation
 IF OUR PRECLINICAL TESTING AND CLINICAL TRIALS ARE NOT SUCCESSFUL, WE WILL NOT OBTAIN REGULATORY
APPROVAL FOR COMMERCIAL SALE OF OUR PRODUCT CANDIDATES.
       
    
    Ongoing discussions with the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;
    
    Delays in enrolling patients and volunteers into clinical trials;
    
    Lower than anticipated retention rate of patients and volunteers in clinical trials;
    
    Negative or inconclusive results of clinical trials or adverse medical events during a
clinical trial could cause a clinical trial to be repeated or a program to be terminated,
even if other studies or trials related to the program are successful;
    
    Insufficient supply or deficient quality of drug candidate materials or other materials
necessary for the conduct of our clinical trials;
    
    Serious and unexpected drug-related side-effects experienced by participants in our clinical trials; or
 30




---



##### Table of Contents




    
    The placement of a clinical trial on hold.
 OUR PRODUCT CANDIDATES ARE SUBJECT TO RIGOROUS REGULATORY REVIEW AND, EVEN IF APPROVED, REMAIN
SUBJECT TO EXTENSIVE REGULATION.
    
    
    Regulatory approvals may impose significant limitations on the uses for which any
approved products may be marketed;
    
    Any marketed product and its manufacturer are subject to periodic reviews and audits, and
any discovery of previously unrecognized problems with a product or manufacturer could
result in suspension or limitation of approvals;
    
    Changes in existing regulatory requirements, or the enactment of additional regulations
or statutes, could prevent or affect the timing of our ability to achieve regulatory
compliance. Federal and state laws, regulations and policies may be changed with possible
retroactive effect, and how these rules actually operate can depend heavily on
administrative policies and interpretation over which we have no control, and we may possess
inadequate experience to assess their full impact upon our business; and
    
    The approval may impose significant restrictions on the indicated uses, conditions for
use, labeling, advertising, promotion, marketing and/or production of such product, and may
impose ongoing requirements for post-approval studies, including additional research and
development and clinical trials.
 OUR PRODUCTS COULD BE SUBJECT TO RESTRICTIONS OR WITHDRAWAL FROM THE MARKET AND WE MAY BE SUBJECT
TO PENALTIES IF WE FAIL TO COMPLY WITH REGULATORY REQUIREMENTS, OR IF WE EXPERIENCE UNANTICIPATED
PROBLEMS WITH OUR PRODUCTS, WHEN AND IF ANY OF THEM ARE APPROVED.
  31




---



##### Table of Contents




    
    Restrictions on such products, manufacturers or manufacturing processes;
    
    Warning letters;
    
    Withdrawal of the products from the market;
    
    Refusal to approve pending applications or supplements to approved applications that we submit;
    
    Recall;
    
    Fines;
    
    Suspension or withdrawal of regulatory approvals;
    
    Refusal to permit the import or export of our products;
    
    Product seizure; and
    
    Injunctions or the imposition of civil or criminal penalties.
 FAILURE TO OBTAIN REGULATORY APPROVAL IN FOREIGN JURISDICTIONS WOULD PREVENT US FROM MARKETING OUR
PRODUCTS ABROAD.
  FOREIGN GOVERNMENTS TEND TO IMPOSE STRICT PRICE CONTROLS WHICH MAY ADVERSELY AFFECT OUR REVENUES,
IF ANY.
  Risks Related to our Intellectual Property
 IF WE ARE UNABLE TO SECURE ADEQUATE PATENT PROTECTION FOR OUR TECHNOLOGIES, THEN WE MAY NOT BE ABLE
TO COMPETE EFFECTIVELY AS A BIOTECHNOLOGY COMPANY.
   32




---



##### Table of Contents




    
    Our ability to protect our technologies could be delayed or negatively affected if the
United States Patent and Trademark Office, or USPTO, requires additional experimental
evidence that our technologies work;
    
    Our competitors may develop similar technologies or products, or duplicate any technology developed by us;
    
    Our competitors may develop products which are similar to ours but which do not infringe our patents or products;
    
    Our competitors may successfully challenge one or more of our patents in an interference or litigation proceeding;
    
    Our patents may infringe the patents or rights of other parties who may decide not to
grant a license to us. We may have to change our products or processes, pay licensing fees
or stop certain activities because of the patent rights of third parties which could cause
additional unexpected costs and delays;
    
    Patent law in the fields of healthcare and biotechnology is still evolving and future
changes in such laws might conflict with our existing and future patent rights, or the
rights of others;
    
    Our collaborators, employees and consultants may breach the confidentiality agreements
that we enter into to protect our trade secrets and proprietary know-how. We may not have
adequate remedies for such breach; and
    
    There may be disputes as to the ownership of technological information developed by
consultants, scientific advisors or other third parties which may not be resolved in our
favor.
 WE IN-LICENSE A SIGNIFICANT PORTION OF OUR INTELLECTUAL PROPERTY AND IF WE FAIL TO COMPLY WITH OUR
OBLIGATIONS UNDER ANY OF THE RELATED AGREEMENTS, WE COULD LOSE LICENSE RIGHTS THAT ARE NECESSARY TO
DEVELOP OUR PRODUCT CANDIDATES.
  IF WE BECOME INVOLVED IN PATENT LITIGATION OR OTHER PROCEEDINGS RELATED TO A DETERMINATION OF
RIGHTS, WE COULD INCUR SUBSTANTIAL COSTS AND EXPENSES, SUBSTANTIAL LIABILITY FOR DAMAGES OR BE
REQUIRED TO STOP OUR PRODUCT DEVELOPMENT AND COMMERCIALIZATION EFFORTS.
   33




---



##### Table of Contents



CONFIDENTIALITY AGREEMENTS WITH EMPLOYEES AND OTHERS MAY NOT ADEQUATELY PREVENT DISCLOSURE OF TRADE
SECRETS AND OTHER PROPRIETARY INFORMATION.
  Risks Related to our Dependence on Third Parties
 IF ANY COLLABORATOR TERMINATES OR FAILS TO PERFORM ITS OR THEIR OBLIGATIONS UNDER AGREEMENTS WITH
US, THE DEVELOPMENT AND COMMERCIALIZATION OF OUR PRODUCT CANDIDATES COULD BE DELAYED OR TERMINATED.
   
    
    Larry I. Benowitz, Ph.D., Director, Laboratories for Neuroscience Research in
Neurosurgery, Childrens Hospital, Boston; Associate Professor of Neuroscience, Department
of Surgery, Harvard Medical School.
    
    Joseph R. Bianchine, M.D., Ph.D., F.A.C.P., F.A.C.C.P., former Senior Scientific Advisor,
Schwarz Pharma AG.
    
    Alan J. Fischman, M.D., Ph.D., Director, Department of Nuclear Medicine, Massachusetts
General Hospital; Professor of Radiology, Harvard Medical School.
    
    Zhigang He, Ph.D., BM, Research Associate, Department of Neurology, Childrens Hospital
Boston; Associate Professor of Neurology, Department of Neurology, Harvard Medical School.
    
    Robert S. Langer, Jr. Sc.D., Director, Boston Life Sciences, Inc., Institute Professor of
Chemical and Biomedical Engineering, Massachusetts Institute of Technology.
    
    Peter Meltzer, Ph.D., President, Organix, Inc., Woburn, MA.
 34




---



##### Table of Contents




    
    Beacon Bioscience in Doylestown, Pennsylvania which performs services for us including
ALTROPANE SPECT evaluations and image management;
    
    Chemic Laboratories in Canton, Massachusetts which provides ALTROPANE chemical
intermediate material, INOSINE drug substance, and performs certain analytic services for
our preclinical programs;
    
    Childrens Hospital Boston in Boston, Massachusetts where certain of our collaborating
scientists perform their research efforts;
    
    Harvard Medical School in Boston, Massachusetts where certain of our collaborating
scientists perform their research efforts;
    
    INC Research in Raleigh, North Carolina which performs services for us including clinical
and medical monitoring, statistical analysis and data management services;
    
    Massachusetts General Hospital, Boston, Massachusetts where certain of our collaborating
scientists perform their research efforts;
    
    MDS Nordion in Vancouver, British Colombia which manufactures the SPECT ALTROPANE molecular imaging agent;
    
    Medifacts International in Rockville, Maryland which is our ECG core laboratory and provides cardiac safety services; and
    
    Organix in Woburn, Massachusetts which provides non-radioactive ALTROPANE for FDA
mandated studies and synthesizes our compounds for the treatment of PD and for axon
regeneration.
     35




---



##### Table of Contents



IF WE ARE UNABLE TO MAINTAIN OUR KEY WORKING RELATIONSHIPS WITH OUR KEY COLLABORATORS, INCLUDING
HARVARD AND ITS AFFILIATES AND CHILDRENS MEDICAL CENTER CORPORATION, WE MAY NOT BE SUCCESSFUL
SINCE SUBSTANTIALLY ALL OF OUR CURRENT TECHNOLOGIES WERE LICENSED FROM, AND MOST OF OUR RESEARCH
AND DEVELOPMENT ACTIVITIES WERE PERFORMED BY, SUCH COLLABORATORS. WE EXPECT THAT A SUBSTANTIAL
PORTION OF OUR FUTURE DEVELOPMENT EFFORTS WILL BE BASED UPON TECHNOLOGIES DEVELOPED BY AND RESEARCH
AND DEVELOPMENT PERFORMED BY THESE COLLABORATORS.
   
    
    ALTROPANE molecular imaging agent compositions and methods of use;
    
    Technetium-based molecular imaging agent compositions and methods of use;
    
    Axon regeneration methods of use; and
    
    DAT blocker compositions and methods of use.
   
    
    An initial licensing fee payment upon the execution of the agreement and annual license
maintenance fee;
    
    Reimbursement payments for all patent related costs incurred by the licensor, including
fees associated with the filing of continuation-in-part patent applications;
    
    Milestone payments as licensed technology progresses through each stage of development
(filing of IND, completion of one or more clinical stages and submission and approval of an
NDA); and
    
    Royalty payments on the sales of any products based on the licensed technology.
    36




---



##### Table of Contents



IF WE ARE UNABLE TO ESTABLISH, MAINTAIN AND RELY ON NEW COLLABORATIVE RELATIONSHIPS, THEN WE MAY
NOT BE ABLE TO SUCCESSFULLY DEVELOP AND COMMERCIALIZE OUR TECHNOLOGIES.
  
    
    We will be able to enter into such collaborations on economically feasible and otherwise
acceptable terms and conditions;
    
    Such collaborations will not require us to undertake substantial additional obligations
or require us to devote additional resources beyond those we have identified at present;
    
    Any of our collaborators will not breach or terminate their agreements with us or
otherwise fail to conduct their activities on time, thereby delaying the development or
commercialization of the technology for which the parties are collaborating; and
    
    The parties will not dispute the ownership rights to any technologies developed under
such collaborations.
 IF ONE OF OUR COLLABORATORS WERE TO CHANGE ITS STRATEGY OR THE FOCUS OF ITS DEVELOPMENT AND
COMMERCIALIZATION EFFORTS WITH RESPECT TO OUR RELATIONSHIP, THE SUCCESS OF OUR PRODUCT CANDIDATES
AND OUR OPERATIONS COULD BE ADVERSELY AFFECTED.
  
    
    The amount and timing of resources that our collaborators may devote to the product candidates;
    
    Our collaborators may experience financial difficulties;
    
    We may be required to relinquish important rights such as marketing and distribution rights;
    
    Should a collaborator fail to develop or commercialize one of our product candidates, we
may not receive any future milestone payments and will not receive any royalties for the
product candidate;
    
    Business combinations or significant changes in a collaborators business strategy may
also adversely affect a collaborators willingness or ability to complete its obligations
under any arrangement;
    
    A collaborator may not devote sufficient time and resources to any collaboration with us,
which could prevent us from realizing the potential commercial benefits of that
collaboration;
    
    A collaborator may terminate their collaborations with us, which could make it difficult
for us to attract new collaborators or adversely affect how we are perceived in the business
and financial communities; and
 37




---



##### Table of Contents




    
    A collaborator could move forward with a competing product candidate developed either
independently or in collaboration with others, including our competitors.
  Risks Related to Competition
 WE ARE ENGAGED IN HIGHLY COMPETITIVE INDUSTRIES DOMINATED BY LARGER, MORE EXPERIENCED AND BETTER
CAPITALIZED COMPANIES.
  
    
    Many of our potential competitors in the field of CNS research have significantly greater
experience than we do in completing preclinical and clinical testing of new pharmaceutical
products, the manufacturing and commercialization process, and obtaining FDA and other
regulatory approvals of products;
    
    Many of our potential competitors have products that have been approved or are in late
stages of development;
    
    Many of our potential competitors may develop products or other novel technologies that
are more effective, safer or less costly than any that we are developing;
    
    Many of our potential competitors have collaborative arrangements in our target markets
with leading companies and research institutions;
    
    The timing and scope of regulatory approvals for these products;
    
    The availability and amount of third-party reimbursement;
    
    The strength of our patent position;
    
    Many of our potential competitors are in a stronger financial position than us, and are
thus better able to finance the significant cost of developing, manufacturing and selling
new products; and
    
    Companies with established positions and prior experience in the pharmaceutical industry
may be better able to develop and market products for the treatment of those diseases for
which we are trying to develop products.
  38




---



##### Table of Contents



IF WE ARE UNABLE TO COMPETE EFFECTIVELY, OUR PRODUCT CANDIDATES MAY BE RENDERED NONCOMPETITIVE OR
OBSOLETE.
  IF THIRD-PARTY PAYORS DO NOT ADEQUATELY REIMBURSE OUR CUSTOMERS FOR ANY OF OUR PRODUCTS THAT ARE
APPROVED FOR MARKETING, THEY MIGHT NOT BE ACCEPTED BY PHYSICIANS AND PATIENTS OR PURCHASED OR USED,
AND OUR REVENUES AND PROFITS WILL NOT DEVELOP OR INCREASE.
   
    
    Significant uncertainty exists as to the reimbursement status of newly approved health care products;
    
    Third-party payors are increasingly challenging the prices charged for medical products and services;
    
    Adequate insurance coverage and reimbursement may not be available to allow us to charge
prices for products which are adequate for us to realize an appropriate return on our
development costs. If adequate coverage and reimbursement are not provided for use of our
products, the market acceptance of these products will be negatively affected;
    
    Health maintenance organizations and other managed care companies may seek to negotiate
substantial volume discounts for the sale of our products to their members thereby reducing
our profit margins; and
    
    In recent years, bills proposing comprehensive health care reform have been introduced in
Congress that would potentially limit pharmaceutical prices and establish mandatory or
voluntary refunds. It is uncertain if any legislative proposals will be adopted and how
federal, state or private payors for health care goods and services will respond to any
health care reforms.
   39




---



##### Table of Contents



MEDICARE PRESCRIPTION DRUG COVERAGE LEGISLATION AND FUTURE LEGISLATIVE OR REGULATORY REFORM OF THE
HEALTH CARE SYSTEM MAY AFFECT OUR ABILITY TO SELL OUR PRODUCT CANDIDATES PROFITABLY.
    WE HAVE LIMITED MANUFACTURING CAPACITY AND MARKETING INFRASTRUCTURE AND EXPECT TO BE HEAVILY
DEPENDENT UPON THIRD PARTIES TO MANUFACTURE AND MARKET APPROVED PRODUCTS.
   40




---



##### Table of Contents



USE OF THIRD PARTY MANUFACTURERS MAY INCREASE THE RISK THAT WE WILL NOT HAVE ADEQUATE SUPPLIES OF
OUR PRODUCT CANDIDATES.
  
    
    Reliance on the third party for regulatory compliance and quality assurance;
    
    The possible breach of the manufacturing agreement by the third party; and
    
    The possible termination or nonrenewal of the agreement by the third party, based on its
own business priorities, at a time that is costly or inconvenient for us.
  41




---



##### Table of Contents



Risks Related to Employees and Growth
 IF WE ARE UNABLE TO RETAIN OUR KEY PERSONNEL AND/OR RECRUIT ADDITIONAL KEY PERSONNEL IN THE FUTURE,
THEN WE MAY NOT BE ABLE TO OPERATE EFFECTIVELY.
   Risks Related to our Stock
 OUR STOCK PRICE MAY CONTINUE TO BE VOLATILE AND CAN BE AFFECTED BY FACTORS UNRELATED TO OUR
BUSINESS AND OPERATING PERFORMANCE.
  
    
    Announcements of technological innovations or new commercial products by our competitors or us;
    
    Announcements in the scientific and research community;
    
    Developments concerning proprietary rights, including patents;
    
    Delay or failure in initiating, conducting, completing or analyzing clinical trials or
problems relating to the design, conduct or results of these trials;
    
    Announcement of FDA approval or non-approval of our product candidates or delays in the FDA review process;
    
    Developments concerning our collaborations;
    
    Publicity regarding actual or potential medical results relating to products under development by our competitors or us;
    
    Failure of any of our product candidates to achieve commercial success;
    
    Our ability to manufacture products to commercial standards;
    
    Conditions and publicity regarding the life sciences industry generally;
    
    Regulatory developments in the United States and foreign countries;
    
    Changes in the structure of health care payment systems;
 42




---



##### Table of Contents




    
    Period-to-period fluctuations in our financial results or those of companies that are perceived to be similar to us;
    
    Departure of our key personnel;
    
    Future sales of our common stock;
    
    Investors perceptions of us, our products, the economy and general market conditions;
    
    Differences in actual financial results versus financial estimates by securities analysts and changes in those estimates; and
    
    Litigation.
 43




---



##### Table of Contents



Item 6  Exhibits
 31.1
    
    Certification pursuant to Rule 13a-14(a) and 15d-14(a) of the
Securities Exchange Act, as adopted pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002 (Chief Executive Officer).31.2
    
    Certification pursuant to Rule 13a-14(a) and 15d-14(a) of the
Securities Exchange Act, as adopted pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002 (Chief Financial Officer).32.1
    
    Certification of the Chief Executive Officer pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.32.2
    
    Certification of the Chief Financial Officer pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
 44




---



##### Table of Contents



SIGNATURES
  BOSTON LIFE SCIENCES, INC
(Registrant)DATE: November 14, 2006
    
    /s/ PETER G. SAVASPeter G. SavasChief Executive Officer(Principal Executive Officer)DATE: November 14, 2006
    
    /s/ KENNETH L. RICE, JR.Kenneth L. Rice, Jr.Executive Vice President Finance and AdministrationAnd Chief Financial Officer(Principal Financial and Accounting Officer)
 45